Amgen(US:AMGN) Prnewswire·2025-08-01 20:01Core Points - Amgen's Board of Directors declared a dividend of $2.38 per share for Q3 2025, payable on September 12, 2025, to stockholders of record as of August 22, 2025 [1] - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [2] - The company has received multiple accolades, including being named one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [3] Company Overview - Amgen has over 40 years of experience in the biotechnology industry and utilizes advanced technology and human genetic data to drive innovation [2] - The company is recognized for its commitment to research and development, maintaining a broad and deep pipeline of medicines [2] Recognition and Market Position - In 2024, Amgen was recognized by Fast Company and Forbes for its innovation and employer status, highlighting its strong market position [3] - As a component of major stock indices, Amgen is considered one of the largest and most innovative non-financial companies [3]